Our top pick for
Codexis, Inc is a biotechnology business based in the US. Codexis shares (CDXS) are listed on the NASDAQ and all prices are listed in US Dollars. Codexis employs 161 staff and has a trailing 12-month revenue of around USD$70.2 million.
Since the stock market crash in March caused by coronavirus, Codexis's share price has had significant positive movement.
Its last market close was USD$15.85, which is 11.67% up on its pre-crash value of USD$14 and 88.02% up on the lowest point reached during the March crash when the shares fell as low as USD$8.43.
If you had bought USD$1,000 worth of Codexis shares at the start of February 2020, those shares would have been worth USD$622.33 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$989.36.
|Latest market close||USD$15.85|
|52-week range||USD$8.43 - USD$18.87|
|50-day moving average||USD$12.5979|
|200-day moving average||USD$12.0159|
|Wall St. target price||USD$18.83|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.26|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-18)||-2.40%|
|1 month (2020-10-23)||9.92%|
|3 months (2020-08-25)||18.64%|
|6 months (2020-05-22)||41.39%|
|1 year (2019-11-25)||0.96%|
|2 years (2018-11-23)||-12.19%|
|3 years (2017-11-24)||153.60%|
|5 years (2015-11-25)||311.69%|
|Revenue TTM||USD$70.2 million|
|Gross profit TTM||USD$19 million|
|Return on assets TTM||-6.33%|
|Return on equity TTM||-14.77%|
|Market capitalisation||USD$843.1 million|
TTM: trailing 12 months
There are currently 4.8 million Codexis shares held short by investors – that's known as Codexis's "short interest". This figure is 3.8% up from 4.6 million last month.
There are a few different ways that this level of interest in shorting Codexis shares can be evaluated.
Codexis's "short interest ratio" (SIR) is the quantity of Codexis shares currently shorted divided by the average quantity of Codexis shares traded daily (recently around 289117.64350453). Codexis's SIR currently stands at 16.55. In other words for every 100,000 Codexis shares traded daily on the market, roughly 16550 shares are currently held short.
However Codexis's short interest can also be evaluated against the total number of Codexis shares, or, against the total number of tradable Codexis shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Codexis's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Codexis shares in existence, roughly 80 shares are currently held short) or 0.0834% of the tradable shares (for every 100,000 tradable Codexis shares, roughly 83 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Codexis.
Find out more about how you can short Codexis stock.
We're not expecting Codexis to pay a dividend over the next 12 months.
Over the last 12 months, Codexis's shares have ranged in value from as little as $8.43 up to $18.87. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Codexis's is 0.8235. This would suggest that Codexis's shares are less volatile than average (for this exchange).
Codexis, Inc. discovers, develops, and sells protein catalysts. It offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering protein catalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.
Everything we know about the Qilian International Holding Group IPO, plus information on how to buy in.
Everything we know about the AbCellera Biologics IPO, plus information on how to buy in.
Steps to owning and managing CALM, with 24-hour and historical pricing before you buy.
Steps to owning and managing CRR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BG, with 24-hour and historical pricing before you buy.
Steps to owning and managing BCLI, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLBD, with 24-hour and historical pricing before you buy.
Steps to owning and managing BDTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing RILYO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASPN, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.